CAR-T Myeloma:China’s Fifth CAR-T Cell Therapy Zevorcabtagene Autoleucel Approved for Marketing
CAR-T Myeloma:China’s Fifth CAR-T Cell Therapy Zevorcabtagene Autoleucel Approved for Marketing On March 5, 2024, China’s fifth CAR-T cell therapy, Zevorcabtagene Autoleucel(trade name:...